ADC Analytical Development
& Quality Control

Build an analytical program that helps teams understand the molecule, guide
development decisions, and move with confidence from early characterization to commercial release.

Product Quality & Compliance Excellence Analytical Strategy Across the Full ADC Development Path

ADC analytical strategy has to account for the antibody, the linker-payload, and the final conjugated product as one quality story. DES Pharma helps sponsors build analytical development and QC programs that support DAR control, conjugation heterogeneity assessment, free payload monitoring, unconjugated antibody measurement, potency, purity, and stability across the full development path.

For ADCs, the right method set depends on the question being asked and the stage of the program. HIC-HPLC, RP-HPLC, SEC-HPLC, LC-MS, intact mass, peptide mapping, CE-SDS, and cell-based potency assays all have a place when they are selected with a clear purpose. We help teams choose, develop, qualify, transfer, and maintain methods that remain useful from early development through GMP QC and regulatory submission.

🔬

ADC Analytical & QC Focus Areas

Where analytical work creates the most value for ADC programs

Our analytical work concentrates on clear DAR understanding, practical impurity testing, useful potency assays, and a realistic path from development into QC.

DAR Profiling & Drug Load Distribution

HIC-HPLC / RP-HPLC / SEC-HPLC / CE-SDS

Free Payload & Residual Linker Analysis

Unconjugated Antibody Assessment

Aggregate & Fragment Monitoring

Potency & Bioassay Strategy

Linker Stability & Forced Degradation

Reference Standard Strategy
Method Qualification, Validation & Transfer
Release, Stability & Comparability Panel Design

Representative Analytical Services

Analytical Control Strategy Critical Quality Attributes &
Recommended Control Methods

ADC control strategy works best when orthogonal methods are used to answer specific
quality questions around identity, drug loading, purity, potency, and stability. One assay rarely
tells the full story.

 

Analytical Control Strategy Critical Quality Attributes & Recommended Control Methods

Analytical Focus Area Analytical Approach / Considerations
DAR & Drug Load Distribution HIC-HPLC, RP-HPLC, and LC-MS methods to define average DAR and the distribution of loaded species, from DAR0 (unconjugated) through high-loaded fractions.
Intact Mass Confirmation High-resolution LC-MS to confirm conjugate mass profile and assess overall load state, identifying major and minor conjugated species at the intact protein level.
Conjugation Site Characterization Peptide mapping and reduced-chain or subunit mass analysis for site occupancy and heterogeneity, critical for site-specific conjugation platform characterization and IND filing support.
Free Payload & Residual Linker-Payload Reverse-phase methods with sensitivity adequate for low-level residual species and process carryover, with limits established based on payload potency and ICH Q3A/Q3B thresholds.
Unconjugated Antibody Orthogonal chromatographic methods, including HIC-HPLC and affinity-based approaches, to quantify DAR0 species within the ADC bulk and support purification process characterization.
Aggregates & Fragments SEC-based monitoring as the primary method, supported by orthogonal approaches such as DLS, AUC, or AF4 when structural clarification of higher-order species is needed.
Potency Cell-based cytotoxicity, binding, internalization, or other mode-of-action-based assays suitable for the product stage, with qualification and validation planning aligned to ICH Q2(R2) and current bioassay expectations.
Linker Stability Stress and real-time stability-indicating methods tracking deconjugation, payload release, or related degradation, with forced degradation study design aligned to the linker chemistry and payload class.

Our Frameworks Guiding Analytical Strategy Through Data
AD & QC Services for ADC Programs

Analytical Development and Quality Control serve different but connected functions. We build programs where both frameworks reinforce each other, so methods developed in AD are ready to transfer and use in QC.

Analytical Development

Method design, development, and characterization strategy

Quality Control

Release testing, method lifecycle, and QC program governance

Integrated Analytical CMC Analytical Strategy That Carries Into QC

A good ADC analytical package does more than generate test results. It shows how process choices affect product quality and gives technical, quality, and regulatory teams a clearer basis for decision-making. DES Pharma builds analytical strategies that connect early characterization work with later QC use, so the methods selected at the start remain practical to qualify, transfer, validate, and maintain in a GMP setting.

DAR Understanding

DAR analysis is linked to process interpretation and product performance, so chromatographic data informs both manufacturing decisions and specification design, not just batch release.

Practical Impurity Assays

Methods for free payload, linker-related species, fragments, and aggregates built around realistic sensitivity targets, practical sample handling, and GMP-compatible workflows.

Potency Strategy

Bioassay design aligned with the ADC's mode of action and stage of development, from early relative potency assays through validated QC bioassays suitable for commercial release.

Stability Insight

Linker integrity monitoring, payload release risk profiling, and degradation pathway characterization to support shelf-life justification, storage condition selection, and comparability strategies.

QC Transferability

Transferability criteria, system suitability parameters, and method performance acceptance limits are built into analytical development, so transfer to CDMOs and contract labs is straightforward, not remedial.

Why DES Pharma for ADC Analytics Driving Data-Backed Decisions
At Every Stage of Development

Our analytical consulting integrates scientific depth with QC practicality, so the work done in development becomes an asset in GMP operations and regulatory review.

Fit-for-Purpose Methods

Methods designed around the decision each development stage actually needs, not a fixed panel applied regardless of molecule, platform, or program maturity.

Orthogonal Characterization

Critical quality attributes evaluated using multiple independent techniques so no single method carries the entire quality picture for a complex conjugated molecule.

Transfer-Ready QC Thinking

QC transferability is built into analytical development from the start, reducing the rework, OOS investigations, and timeline delays that arise when QC requirements are addressed late.

Lifecycle-Aligned Strategy

Method development through validation and ongoing maintenance framed as a connected program under ICH Q14 and Q2(R2) analytical lifecycle expectations.

Comparability Support

Analytical comparability packages for process changes, site transfers, scale changes, and material updates, with the documentation depth needed for CMC filings and post-approval variations.

Decision-Focused Data

Analytical outputs structured to help technical, quality, and regulatory teams move forward, not just data packages that meet a minimum test panel requirement.

Analytical Package Design Representative ADC Analytical Package

A complete ADC analytical program addresses the full quality profile of the conjugate, from structural identity and drug loading through purity, potency, and real-time stability monitoring.

Clinical Supply Chain Consulting

Identity & Structural Confirmation

Intact mass, subunit mass, and peptide mapping to confirm conjugate identity, conjugation site occupancy, and structural integrity at each development stage.

DAR & Conjugation Heterogeneity

Average DAR, drug load distribution, and species-level characterization using orthogonal methods, linked to process control targets and specification development.

Purity Profile

Aggregate, fragment, unconjugated antibody, and high-DAR species monitoring, with orthogonal support when SEC alone is insufficient for structural resolution.

Residual Free Payload & Process Impurities

Sensitive RP-based methods for free drug and related linker-payload species, with limits grounded in payload potency, safety data, and regulatory impurity thresholds.

Potency & Binding Characterization

Stage-appropriate potency assays from early relative bioassays through qualified or validated GMP QC methods, aligned to the product's mechanism of action.

Stability-Indicating Methods

Release and shelf-life stability panels covering DAR stability, linker integrity, aggregate formation, payload retention, and potency maintenance under ICH storage conditions.

Get Started Build an ADC Analytical Strategy That Supports Development, Transfer, and QC Use

Connect with our analytical team to discuss your DAR control approach,
potency strategy, method lifecycle plan, or QC transfer readiness.